A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

Summary

Phase 1b Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)

Timeline

Start

2025-10

Primary completion

2027-04

Completion

2028-01

Drugs

Indications